Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 5/2013

01-10-2013 | Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

β3-Receptor Agonists for Overactive Bladder—New Frontier or More of the Same?

Author: Karl-Erik Andersson

Published in: Current Urology Reports | Issue 5/2013

Login to get access

Abstract

The new information generated over the last decade on the physiology/pharmacology of the normal bladder and on the pathophysiology of the overactive bladder has resulted in the introduction of a new therapeutic principle, β3-adrenoceptor (AR) agonism, and the approval of mirabegron, a selective agonist at β3-ARs. It may be asked in what respects the β3-AR agonists as a group, and mirabegron in particular, differ from the antimuscarinics, and what can clinically be gained by the β3-AR agonists. In this short review, the mechanisms of action, clinical efficacy, and adverse effect profiles of the two groups of drugs are compared and discussed.
Literature
1.
Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults:AUA/SUFU guideline. American Urological Association; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. J Urol. 2012;188(6 Suppl):2455–63.PubMedCrossRef
2.
Lucas MG, Bosch RJ, Burkhard FC, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2012;62(6):1130–42.PubMedCrossRef
3.
Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–62.PubMedCrossRef
4.
Novara G, Galfano A, Secco S, et al. Systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54(4):740–63.PubMedCrossRef
5.
•• Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of urinary incontinence. In: Incontinence. ed by AbramsP, Cardozo L, Khoury A, Wein A. 5th International Consultation on Incontinence, Paris February 2012, ICUD-EAU 2013:625–728. Up-to-date review of current treatments.
6.
Andersson KE, Martin N, Nitti V. Selective β3-Adrenoceptor Agonists in the Treatment of the Overactive Bladder. J Urol. 2013b Feb 28. [Epub ahead of print]
7.
Ursino MG, Vasina V, Raschi E, Crema F, De Ponti F. The beta3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res. 2009;59(4):221–34.PubMedCrossRef
8.
Andersson KE. Muscarinic acetylcholine receptors in the urinary tract. Handb Exp Pharmacol. 2011;202:319–44.PubMedCrossRef
9.
Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987–1006.PubMedCrossRef
10.
Andersson KE. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol. 2011;59(3):377–86.PubMedCrossRef
11.
Roosen A, Chapple CR, Dmochowski RR, et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009;56(5):810–9.PubMedCrossRef
12.
Hood B, Andersson KE. Common theme for drugs effective in overactive bladder treatment: Inhibition of afferent signaling from the bladder. Int J Urol. 2013;20(1):21–7.PubMedCrossRef
13.
Gillespie JI. The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int. 2004;93(4):478–83.PubMedCrossRef
14.
15.
16.
Iggo A. Tension receptors in the stomach and the urinary bladder. J Physiol. 1955;128(3):593–607.PubMed
17.
Biers SM, Reynard JM, Brading AF. The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int. 2006;98(6):1310–4.PubMedCrossRef
18.
Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321(2):642–7.PubMedCrossRef
19.
Svalø J, Nordling J, Bouchelouche K, et al. The novel β(3)-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. Eur J Pharmacol. 2012;699(1–3):101–5.PubMed
20.
Hatanaka T, Ukai M, Watanabe M, et al. In vitro and in vivo pharmacological profile of the selective β(3)-adrenoceptor agonistmirabegron in rats. Naunyn Schmiedebergs Arch Pharmacol. 2012 Dec 14. [Epub ahead of print]
21.
Hatanaka T, Ukai M, Watanabe M, et al. Effect of mirabegron, a novel β(3)-adrenoceptor agonist, on bladder function during storage phase in rats. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(1):71–8.PubMedCrossRef
22.
Gillespie JI, Palea S, Guilloteau V, et al. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int. 2012;110(2 Pt 2):E132–42.PubMedCrossRef
23.
Aizawa N, Igawa Y, Nishizawa O, Wyndaele JJ. Effects of CL316,243, a β3 adrenoreceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn. 2010;29:771–6.PubMedCrossRef
24.
• Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012;62(6):1165–73. Nice demonstration of mirabegron effects on bladder Aδ - and C-fiber afferents.PubMedCrossRef
25.
Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;42(14):1243–85.PubMedCrossRef
26.
Andersson KE, Fullhase C, Soler R. Urothelial effects of oral agents for overactive bladder. Curr Urol Rep. 2008;9(6):459–64.PubMedCrossRef
27.
Eltink C, Lee J, Schaddelee M, et al. Single dose pharmacokinetics and absolute bioavailibility of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther. 2012;50(11):838–50.PubMedCrossRef
28.
Krauwinkel W, van Dijk J, Schaddelee M, et al. Pharmacokinetic Properties of Mirabegron, a β(3)-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women. Clin Ther. 2012;34(10):2144.PubMedCrossRef
29.
Füllhase C, Soler R, Westerling-Andersson K, Andersson KE. Beta3-adrenoceptors in the rat sacral spinal cord and their functional relevance in micturition under normal conditions and in a model of partial urethral obstruction. Neurourol Urodyn. 2011;30(7):1382–7.PubMed
30.
Takusagawa S, van Lier JJ, Suzuki K, et al. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012;40(4):815.PubMedCrossRef
31.
Takusagawa S, Yajima K, Miyashita A, et al. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β(3)-adrenoceptor agonist. Xenobiotica. 2012 Apr 18. [Epub ahead of print]
32.
Takusagawa S, Miyashita A, Iwatsubo T, Usui T. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist. Xenobiotica. 2012 Jul 27. [Epub ahead of print]
33.
Basra RK, Wagg A, Chapple C, Cardozo L, Castro-Diaz D, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102(7):774–9.PubMedCrossRef
34.
Sears CL, Lewis C, Noel K, Albright TS, Fischer JR. Overactive bladder medication adherence when medication is free to patients. J Urol. 2010;183:1077–81.PubMedCrossRef
35.
Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–74.PubMedCrossRef
36.
Gomes T, Juurlink DN, Mamdani MM. Comparative adherence to oxybutynin or tolterodine among older patients. Eur J Clin Pharmacol. 2012;68(1):97–9.PubMedCrossRef
37.
Lee YS, Choo MS, Lee JY, Oh SJ, Lee KS. Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial. Int J Clin Pract. 2011;65(9):997–1004.PubMedCrossRef
38.
•• Uvin P, Boudes M, Franken J, et al. Why anticholinergics fail: Oxybutynin and fesoterodine induce a shift from muscarinergic to purinergic transmission in the rat bladder. Eur Urol Suppl. 2013;12:e441. Interesting preliminary report suggestion tolerance development to muscarinic receptor blockade.CrossRef
39.
Chapple CR, Dvorak V, Radziszewski P, et al. On behalf of the Dragon Investigator Group. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013 Mar 8. [Epub ahead of print]
40.
Chapple CR, Dvorak V, Radziszewski P, et al. On behalf of the Dragon Investigator Group. A proof-of-concept study: Mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013 Feb 19. [Epub ahead of print]
41.
Nitti VW, Auerbach S, Martin N, et al. Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder. J Urol. 2013;189(4):1388–95.PubMedCrossRef
42.
Khullar V, Amarenco G, Angulo JC, et al. Efficacy and Tolerability of Mirabegron, a β(3)-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Trial. Eur Urol. 2013;63(2):283–95.PubMedCrossRef
43.
Van Kerrebroeck P, Barkin Z, Castro-Diaz D, et al. Randomised, double-blind, placebo-controlled Phase III study to assess the efficacy and safety of mirabegron 25 mg and 50 mg once daily in overactive bladder (OAB). Beijing: Presented at the International Continence Society Meeting; 2012.
44.
•• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305. The first long-term study of mirabegron with a toterodine treatment arm.PubMedCrossRef
45.
Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;18:1. CD005429.
46.
Kessler TM, Bachmann LM, Minder C, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One. 2011;6(2):e16718.PubMedCrossRef
47.
Andersson KE, Olshansky B. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int. 2007;100(5):1007–14.
48.
Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharm. 2011;72:186–96.CrossRef
49.
Nitti V, Rosenberg S, Mitcheson HD, et al. Randomized, multicenter phase II study evaluating the urodynamic safety of mirabegron in males with lower urinary tract symptoms (LUTS) and bladder outlet. J Urol. 2012;187(4 suppl):e756.CrossRef
50.
51.
• Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study. Clin Pharmacol Ther. 2012;92(6):696. Important documentation of cardiac effects of mirabegron.PubMedCrossRef
52.
Rekik M, Rouget C, Palea S, et al. Effects of combining antimuscarinics and β3-adrenoceptor agonists on contractions induced by electrical field stimulation of rat isolated urinary bladder strips. Eur Urol Suppl. 2013;12:e440.CrossRef
53.
Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - Efficacy results from a phase 2 study (Symphony). J Urol Suppl. 2013;189(4S):e803.CrossRef
Metadata
Title
β3-Receptor Agonists for Overactive Bladder—New Frontier or More of the Same?
Author
Karl-Erik Andersson
Publication date
01-10-2013
Publisher
Springer US
Published in
Current Urology Reports / Issue 5/2013
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-013-0335-8

Other articles of this Issue 5/2013

Current Urology Reports 5/2013 Go to the issue

Testis and Penile Cancer (M Manoharan and J Sheinfeld, Section Editors)

Late Relapse of Testis Cancer

Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

Management of OAB in Those Over Age 65

Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

Retropubic Versus Transobturator Slings—Are the Outcomes Changing with Time?

Surgical Techniques (J Cadeddu and A Stenzl, Section Editors)

Reducing Morbidity of Pelvic and Retroperitoneal Lymphadenectomy

Testis and Penile Cancer (M Manoharan and J Sheinfeld, Section Editors)

Controversies in the Management of Stage 1 Non-Seminomatous Germ Cell Tumors

Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

Myofascial Trigger Points of the Pelvic Floor: Associations with Urological Pain Syndromes and Treatment Strategies Including Injection Therapy